Find Clinical Drug Pipeline Developments & Deals for Carvedilol

Carvedilol
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Carvedilol

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

98 API Suppliers, 25 USDMF, 24 CEP/COS, 5 JDMF, 15 EU WC, 40 KDMF, 16 NDC API, 40 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

19 Drugs in Development

19 Drugs in Development

INTERMEDIATES

33 Intermediate Suppliers

33 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

536 FDF Dossiers, 72 FDA Orange Book, 262 Europe, 35 Canada, 52 Australia, 30 South Africa, 85 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 12.5MG, TABLET;ORAL - 25MG, TABLET;ORAL - 3.125MG, TABLET;ORAL - 6.25MG

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 17 SPI Pharma, 5 DKSH, 11 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 3 Kirsch Pharma, 1 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 30 BASF, 1 Clariant, 10 Corel Pharma Chem, 5 DFE Pharma, 1 Esteem Industries, 1 Finar, 11 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 4 Ideal Cures, 4 Ingredion Pharma Solutions, 20 Kerry, 2 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 4 Novo Excipients, 3 Pharmatrans-Sanaq, 7 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 18 Roquette, 13 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 Silverline Chemicals, 2 The Dow Chemical Company, 2 Ulanqab Kema New Material, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

76 Fillers, Diluents & Binders, 45 Coating Systems & Additives, 41 Direct Compression, 35 Disintegrants & Superdisintegrants, 33 Granulation, 28 Solubilizers, 27 Thickeners and Stabilizers, 26 Controlled & Modified Release, 20 Taste Masking, 20 Chewable & Orodispersible Aids, 16 Parenteral, 16 Lubricants & Glidants, 15 Co-Processed Excipients, 14 Topical, 14 Film Formers & Plasticizers, 7 Emulsifying Agents, 7 Rheology Modifiers, 6 API Stability Enhancers, 5 Surfactant & Foaming Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents

DIGITAL CONTENT

21 News #PharmaBuzz

21 News #PharmaBuzz

GLOBAL SALES INFORMATION

20 US Medicaid Prescriptions, 190 Regulatory FDF Prices, 5 Annual Reports

MARKET PLACE

16 APIs, 10 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 EDQM, 2 USP, 8 Others

ANALYTICAL

4 BioAnalytical Methods, 3 Analytical Methods

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Dr. Reddy's Laboratories

India

CPhI WW Frankfurt

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Carvedilol

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fasting Conditions

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 08, 2010

Lead Product(s) : Carvedilol

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Dr. Reddy's Laboratories

India

CPhI WW Frankfurt

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Carvedilol

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fed Conditions

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 08, 2010

Lead Product(s) : Carvedilol

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Asan Medical Center

Country

Peptide Process CMC

Not Confirmed

04

West Virginia University

Country

Peptide Process CMC

Not Confirmed

05

Keimyung University

Country

Peptide Process CMC

Not Confirmed

06

Seoul National University Bundang Hospital

Country

Peptide Process CMC

Not Confirmed

07

Children's Oncology Group

Country

Peptide Process CMC

Not Confirmed

08

Chong Kun Dang Pharm

South Korea

Peptide Process CMC

Not Confirmed

09

GSK

United Kingdom

Peptide Process CMC

Not Confirmed

10

Chong Kun Dang Pharm

South Korea

Peptide Process CMC

Not Confirmed

1
2